2025
Consultation patterns in lupus erythematosus: a retrospective review of inpatient and outpatient consultations at a single institution
Xu S, Ramachandran S, Koumpouras F, Vesely M, Little A, Gehlhausen J. Consultation patterns in lupus erythematosus: a retrospective review of inpatient and outpatient consultations at a single institution. Archives Of Dermatological Research 2025, 317: 810. DOI: 10.1007/s00403-025-04287-8.Peer-Reviewed Original ResearchABS0315 TACKLING RHEUMATOLOGY WORKFORCE SHORTAGES WITH A CASE-BASED PRIMARY CARE RHEUMATOLOGY CURRICULUM
Cabrera D, Hsiao B, Koumpouras F. ABS0315 TACKLING RHEUMATOLOGY WORKFORCE SHORTAGES WITH A CASE-BASED PRIMARY CARE RHEUMATOLOGY CURRICULUM. Annals Of The Rheumatic Diseases 2025, 84: 1795-1796. DOI: 10.1016/j.ard.2025.06.1286.Peer-Reviewed Original ResearchPrimary care traineesWorkforce shortagesGeneral practitionersResidency programsFamily medicineKnowledge deficitsUrate-lowering therapyPostgraduate yearPrimary care trainingPrimary care residentsManagement of rheumatic diseasesPrimary care physiciansInternal medicine programsRheumatic diseasesPre-testRisk factorsPost-intervention testsInteractive learning sessionsRA risk factorsUnited StatesPrimary careCare trainingCare residentsPre-test scoresCare physiciansCutaneous lupus features specialized stromal niches and altered retroelement expression
Gehlhausen J, Kong Y, Baker E, Ramachandran S, Koumpouras F, Ko C, Vesely M, Little A, Damsky W, King B, Iwasaki A. Cutaneous lupus features specialized stromal niches and altered retroelement expression. Journal Of Investigative Dermatology 2025 PMID: 40409678, DOI: 10.1016/j.jid.2025.04.033.Peer-Reviewed Original ResearchRetroelement expressionCGAS-STING pathwayRIG-IType I interferonCutaneous lupusCGAS-STINGElevated expression of genesPathway enrichment analysisI interferonExpression of genesResponse to type I interferonsLupus skinRetroelement familiesInterferon-stimulated genesNucleic acid signalsApoptotic signalingSingle-cell RNAMultiple cell typesAcid signalingEnrichment analysisInflammatory cell recruitmentType II interferonInflammatory skin diseaseTumor necrosis factorCell typesANIFROLUMAB EFFECTS ON RESPONSE TO INFLUENZA VACCINE IN SLE
Arriens C, Askanase A, Machua W, Koumpouras F, Smith K, Guthridge J, James J, Merrill J. ANIFROLUMAB EFFECTS ON RESPONSE TO INFLUENZA VACCINE IN SLE. The Journal Of Rheumatology 2025, 52: 231-232. DOI: 10.3899/jrheum.2025-0390.pv244.Peer-Reviewed Original ResearchGeometric mean titersResponse to influenza vaccinationStandard-of-care treatmentSLEDAI Flare IndexInfluenza vaccineAdverse eventsVaccine responseSLE patientsHemagglutination inhibitionEnzyme-linked immunosorbent assayWeek 8Anifrolumab groupControl groupContext of influenza vaccinesModerate to severe SLESeasonal influenza virus vaccinesBaseline to week 8Interferon signalingAnti-influenza IgGInfluenza virus vaccineGeometric mean foldDiscontinuation of treatmentHemagglutinin inhibition assayAdult SLE patientsHerpes zoster reactivationRepresentation of skin of color in patient education materials for discoid lupus erythematosus
Saeed S, Ajoku E, Swallow M, Vesely M, Gehlhausen J, Little A, Koumpouras F, Ramachandran S. Representation of skin of color in patient education materials for discoid lupus erythematosus. Archives Of Dermatological Research 2025, 317: 583. PMID: 40095060, DOI: 10.1007/s00403-025-04094-1.Peer-Reviewed Original ResearchPatient preferences for peer support in cutaneous autoimmune disease: a pilot cross-sectional survey study
Saeed S, Huggins L, Jiang T, Koumpouras F, Ramachandran S. Patient preferences for peer support in cutaneous autoimmune disease: a pilot cross-sectional survey study. Archives Of Dermatological Research 2025, 317: 567. PMID: 40095064, DOI: 10.1007/s00403-025-04077-2.Peer-Reviewed Original ResearchOutcomes following single level posterior lumbar fusion in patients with systemic and discoid lupus: A retrospective national database study
Dhodapkar M, Halperin S, Day W, Saifi C, Rubio D, Koumpouras F, Grauer J, Varthi A. Outcomes following single level posterior lumbar fusion in patients with systemic and discoid lupus: A retrospective national database study. North American Spine Society Journal (NASSJ) 2025, 22: 100604. PMID: 40487382, PMCID: PMC12141882, DOI: 10.1016/j.xnsj.2025.100604.Peer-Reviewed Original ResearchPosterior lumbar fusionSystemic lupus erythematosusDiscoid lupus erythematosusSingle-level posterior lumbar fusionPostoperative adverse eventsMinor adverse eventsAdverse eventsIncreased oddsLupus erythematosusLumbar fusionDiagnosis of discoid lupus erythematosusCohort of systemic lupus erythematosusLevel posterior lumbar fusionsMultivariate analysisDiagnosis of systemic lupus erythematosusDiscoid lupus erythematosus patientsUrinary tract infectionPerioperative adverse outcomesSurgical site infectionAcute kidney injuryDeep vein thrombosisNational database studyHistory of infectionSampled adult patientsMultivariate logistic regressionThe readability of online patient education materials for cutaneous autoimmune connective tissue diseases
Saeed S, Gehlhausen J, Koumpouras F, Ramachandran S. The readability of online patient education materials for cutaneous autoimmune connective tissue diseases. Clinical Rheumatology 2025, 44: 1389-1390. PMID: 39904945, DOI: 10.1007/s10067-025-07353-8.Peer-Reviewed Original ResearchThe spectrum of cutaneous and systemic manifestations associated with anti-PM/Scl: Insights from a single institution case series
Saeed S, Gehlhausen J, Koumpouras F, Ramachandran S. The spectrum of cutaneous and systemic manifestations associated with anti-PM/Scl: Insights from a single institution case series. Journal Of The American Academy Of Dermatology 2025, 92: 1091-1093. PMID: 39756619, DOI: 10.1016/j.jaad.2024.12.033.Peer-Reviewed Original Research
2024
Outcomes following total shoulder arthroplasty in patients with systemic lupus erythematosus
Salib A, Sanchez J, Huggins L, Seddio A, Dhodapkar M, Smith-Voudouris J, Norman M, Koumpouras F, Grauer J. Outcomes following total shoulder arthroplasty in patients with systemic lupus erythematosus. Journal Of Shoulder And Elbow Surgery 2024, 34: e196-e204. PMID: 39154846, DOI: 10.1016/j.jse.2024.07.008.Peer-Reviewed Original ResearchSystemic lupus erythematosus patientsSystemic lupus erythematosusTotal shoulder arthroplastyAdverse eventsImplant survivalLupus erythematosusMultivariate analysisShoulder arthroplastyIncreased oddsTotal shoulder arthroplasty patientsNon-SLE patientsMultivariate logistic regressionImmunomodulatory therapyPostoperative complicationsElixhauser Comorbidity IndexAdult patientsNinety-dayUnivariate analysisSurgical planningComorbidity indexPatient counselingGlenohumeral osteoarthritisPatientsComorbid conditionsOrthopedic-relatedA dual-acting DNASE1/DNASE1L3 biologic prevents autoimmunity and death in genetic and induced lupus models
Stabach P, Sims D, Gomez-Bañuelos E, Zehentmeier S, Dammen-Brower K, Bernhisel A, Kujawski S, Lopez S, Petri M, Goldman D, Lester E, Le Q, Ishaq T, Kim H, Srivastava S, Kumar D, Pereira J, Yarema K, Koumpouras F, Andrade F, Braddock D. A dual-acting DNASE1/DNASE1L3 biologic prevents autoimmunity and death in genetic and induced lupus models. JCI Insight 2024, 9: e177003. PMID: 38888971, PMCID: PMC11383374, DOI: 10.1172/jci.insight.177003.Peer-Reviewed Original ResearchSystemic lupus erythematosusDNASE1L3 deficiencySporadic systemic lupus erythematosusAssociated with systemic lupus erythematosusChromatin degradationDNA accumulationDevelopment of lupusPristane-induced lupusSelf-DNACell free DNAHuman isoformsSystemic lupus erythematosus plasmasDouble knockout miceDNASE1L3Pathogenic effectsFree DNALupus modelEnzymeInducible lupus modelAdult patientsLupus erythematosusKnockout micePediatric populationAutoimmune diseasesDNAChimeric antigen receptors: “CARs” in the fast lane for rheumatology
Johnson N, Koumpouras F. Chimeric antigen receptors: “CARs” in the fast lane for rheumatology. Current Opinion In Rheumatology 2024, 36: 176-183. PMID: 38517338, PMCID: PMC11224568, DOI: 10.1097/bor.0000000000001012.Peer-Reviewed Original ResearchConceptsChimeric antigen receptorCAR-T treatmentCAR-TB cellsAutoimmune diseasesRheumatologic diseasesReview current clinical dataSevere refractory autoimmune diseasesReconstitution of B cellsRefractory autoimmune diseasesTreatment of rheumatologic diseasesB-cell malignanciesCompassionate use programB cell populationsLaboratory remissionRefractory SLECD19-CARField of autoimmunityRefractory diseaseClinical responseNaive phenotypeSevere lupusMultiple myelomaAutoimmune modelsT cells
2023
Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co‐Expression Patterns: A Double‐Blind, Randomized, Placebo‐Controlled, Phase 2 Trial
Merrill J, Guthridge J, Smith M, June J, Koumpouras F, Machua W, Askanase A, Khosroshahi A, Sheikh S, Rathi G, Burington B, Foster P, Matijevic M, Arora S, Wang X, Gao M, Wax S, James J, Zack D. Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co‐Expression Patterns: A Double‐Blind, Randomized, Placebo‐Controlled, Phase 2 Trial. Arthritis & Rheumatology 2023, 75: 2185-2194. PMID: 37459248, DOI: 10.1002/art.42652.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusLoss of improvementPrimary endpointLupus erythematosusWeek 32B cellsEfficacy-evaluable populationImproved disease activityPhase 2 trialProportion of patientsTreatment-related toxicityTreatment of patientsPlacebo-ControlledCorticosteroid injectionDisease activityInfusion reactionsTrough concentrationsPatient subsetsPlasma cellsPatientsSecondary analysisMonoclonal antibodiesStatistical significanceEndpointPlaceboVascular-Targeted Therapy for Systemic Lupus Erythematosus–Associated Vasculitis
Xu S, Patrignelli R, Ramachandran S, Koumpouras F, Desir D, Ko C, Gehlhausen J. Vascular-Targeted Therapy for Systemic Lupus Erythematosus–Associated Vasculitis. JAMA Dermatology 2023, 159: 460-462. PMID: 36884229, DOI: 10.1001/jamadermatol.2023.0077.Peer-Reviewed Original Research
2021
Chapter 11 Interferons and cytokines in SLE pathogenesis and therapy
Koumpouras F, Bucala R. Chapter 11 Interferons and cytokines in SLE pathogenesis and therapy. 2021, 169-180. DOI: 10.1016/b978-0-12-820583-9.00015-4.Peer-Reviewed Original Research
2020
IL-7 receptor alpha defines heterogeneity and signature of human effector memory CD8+ T cells in high dimensional analysis
Shin MS, Kim D, Yim K, Park HJ, You S, Dong X, Koumpouras F, Shaw AC, Fan R, Krishnaswamy S, Kang I. IL-7 receptor alpha defines heterogeneity and signature of human effector memory CD8+ T cells in high dimensional analysis. Cellular Immunology 2020, 355: 104155. PMID: 32619811, PMCID: PMC7415611, DOI: 10.1016/j.cellimm.2020.104155.Peer-Reviewed Original ResearchConceptsSingle-cell RNA-seqHuman effector memory CD8Effector memory CD8T cellsIL-7RαMemory CD8Gene regulationTranscription factorsRNA-seqPossible biological significanceDownstream eventsEM CD8Expression patternsExpressional relationshipDifferential expressionCytokine receptorsComprehensive landscapeHigh-dimensional cytometryBiological significanceIL-7 receptor alphaKey moleculesIL-7 receptor alpha chainReceptor alpha chainBiological implicationsHeterogeneous cell subsetsStand Together and Deliver: Challenges and Opportunities for Rheumatology Education During the COVID‐19 Pandemic
Koumpouras F, Helfgott S. Stand Together and Deliver: Challenges and Opportunities for Rheumatology Education During the COVID‐19 Pandemic. Arthritis & Rheumatology 2020, 72: 1064-1066. PMID: 32270923, PMCID: PMC7262333, DOI: 10.1002/art.41278.Peer-Reviewed Original ResearchDefining heterogeneity and biological signature in human effector memory CD8+ T cells expressing different levels of IL-7 receptor alpha by high-dimensional analysis
Shin M, Kim D, Park H, Dong X, Koumpouras F, Kang I. Defining heterogeneity and biological signature in human effector memory CD8+ T cells expressing different levels of IL-7 receptor alpha by high-dimensional analysis. The Journal Of Immunology 2020, 204: 154.19-154.19. DOI: 10.4049/jimmunol.204.supp.154.19.Peer-Reviewed Original ResearchHuman effector memory CD8EM CD8Effector memory CD8T cellsIL-7RαMemory CD8Cell subsetsIL-7 receptor alphaIL-7 receptor alpha chainT cell subsetsCo-stimulatory moleculesT cell heterogeneityHigh-dimensional single-cell analysisReceptor alpha chainLupus patientsImmune landscapeCell surface moleculesHeterogeneous cell subsetsT-betCD8Effector functionsDifferential expressionReceptor alphaSingle-cell RNA-seq analysisPathologic conditions
2019
FRI0176 PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF A REVERSIBLE B CELL INHIBITOR, XMAB®5871, IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Merrill J, June J, Koumpouras F, Machua W, Khan M, Askanase A, Khosroshahi A, Sheikh S, James J, Guthridge J, Rathi G, Burington B, Foster P, Zack D. FRI0176 PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF A REVERSIBLE B CELL INHIBITOR, XMAB®5871, IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). Annals Of The Rheumatic Diseases 2019, 78: 761-762. DOI: 10.1136/annrheumdis-2019-eular.4234.Peer-Reviewed Original Research98 Results of a phase 2, double-blind, randomized, placebo-controlled study of a reversible B cell inhibitor, XmAb®5871, in systemic lupus erythematosus (SLE)
Merrill J, June J, Koumpouras F, Machua W, Khan M, Askanase A, Sheikh S, Khosroshahi A, Foster P, Zack D. 98 Results of a phase 2, double-blind, randomized, placebo-controlled study of a reversible B cell inhibitor, XmAb®5871, in systemic lupus erythematosus (SLE). 2019, a73-a74. DOI: 10.1136/lupus-2019-lsm.98.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply